

PALIPERIDONE PALMITATE LONG-ACTING INJECTION IN SCHIZOPHRENIC PATIENTS: IMPROVED OF NEGATIVE SYMPTOMS AND METABOLIC RATES.



Suárez Gisbert, E¹.

¹Psychiatry Department. Infanta Sofía University Hospital. Madrid. Spain. European University of Madrid.

OBJETIVES AND BACKGROUND:

Find the differences in the improving of negative symptoms and the metabolic rates in patients with change of neuroleptic (oral to paliperidone palmitate injection). The negative symptoms and metabolic syndrome are a very frequent phenomena with hard treatment.

MATERIAL AND METHODS:

Observational longitudinal study during 12 months. We included all the patients with the diagnosis of schizophrenia, in which we done a change from oral neuroleptic to Palmitate of Paliperidone. Patients with 18 years or more. We used SANSS and CGI-Scale for negative symptoms and metabolic rates (weight, IMC, Glucose, Colessterol, TG and prolactin) and abdominal perimeter.

RESULTS

40 patients was included. 60% are male. Average age 42.48 years. 22% has metabolic disease, 32% with axis IV disease and 28% with toxic substances. Average dosis of palmitate of paliperidone 105 mg/28 days. The reason of change to injection was: No response 38% to oral neuroleptic treatment and side effects 28%. Rest patients wish. Metabolic rates improved: Less in weight, IMC, Glucose, Colessterol, TG and prolactin and abdominal perimeter (Figure 1). The SANSS scale improved (Figures 2 and 3) and CGI scale results improved: Positive, Negative, Depressive, and Cognitive Symptoms, and Global. All of them were statistically significant. ($p < 0,05$)

BIBLIOGRAPHY

1. Kin S, Solari H et al (2012). "Paliperidone palmitate injection for acute and maintenance treatment of schizophrenia in adults". *Patient Prefer Adherence*. 2012; 6:pp. 533-45.
2. Boutros NN, Mucci A et al (2014). "Negative symptoms in schizophrenia". *Clin Schizophr Relat Psychosis*. 2014 Apr;8 (1):pp.28-35B.

CONCLUSIONS

1. The change from oral neuroleptic to palmitate of paliperidone improved metabolic rates and abdominal perimeter.
2. Also improved SANSS and CGI Scale.
3. The palmitate of paliperidone is useful in schizophrenic patients and with less incidence of metabolic side effects and improved of negative symptoms.

FIGURE 1: METABOLIC RATES.

VARIABLES (AVERAGE)	BEFORE PALIPERIDONE	AFTER 1 YEAR WITH PALIPERIDONE IM
WEIGHT	96.5	94.3
BODY MASS INDEX	33.6	32.9
GLUCOSE	111.5	100.9
TRIGLYCERIDES	230.1	165.5
PROLACTINE	61.06	52.35

FIGURE 2: NEGATIVE SYMPTOMS

NEGATIVE SYMPTOMS	BEFORE PALIPERIDONE	AFTER 1 YEAR WITH PALIPERIDONE IM
Affective dullness	17.9	14.77
Praise	12.49	11
Abulia	13.5	10.55
Anhedonia	15.95	13.45
Attention	7.45	6.16
Global score	14.6	11.62

FIGURE 3: SANSS SCALE IMPROVEMENT .

SANSS SCALE	BEFORE PALIPERIDONE	AFTER 1 YEAR WITH PALIPERIDONE IM
SANSS Scale	66.33	54.11